From the Department of Pathology (Lucas, Grenert, Horvai).
the Clinical Cancer Genomics Laboratory (Grenert), University of California, San Francisco, San Francisco.
Arch Pathol Lab Med. 2021 Aug 1;145(8):1009-1017. doi: 10.5858/arpa.2020-0379-OA.
CONTEXT.—: Dedifferentiated chondrosarcoma is a rare adult bone tumor with a dismal prognosis and is composed of a conventional chondrosarcoma juxtaposed to high-grade nonchondrogenic sarcoma. Dedifferentiated chondrosarcomas may represent tumor progression from a differentiated to a primitive histotype.
OBJECTIVE.—: To determine the genetic and molecular events that drive progression from a conventional chondrosarcoma to high grade nonchondrogenic sarcoma.
DESIGN.—: We analyzed the genomic landscape of paired conventional and dedifferentiated components of 11 dedifferentiated chondrosarcoma using targeted next-generation DNA sequencing with immunohistochemical validation. Clinical, radiographic, and pathologic features of tumors were reviewed. Capture-based DNA sequencing targeting the coding regions of 479 cancer genes and select introns was performed.
RESULTS.—: The tumors arose in the femur (n = 4; 36%), scapula (n = 3; 27%), pelvis (n = 3; 27%), and humerus (n = 1; 9%) of 7 men (64%) and 4 women (36%; median age, 61 years). DNA was adequate for sequencing from all 11 dedifferentiated components (100%) and 9 paired conventional chondrosarcoma components (82%). All tumors (100%) harbored either IDH1 p.R132 or IDH2 p.R172S hotspot mutations. Seven tumors (64%) displayed COL2A1 alterations. TERT promoter mutations were present in 5 of 9 pairs (56%) and 2 (22%) additional unpaired dedifferentiated components. IDH1/2, COL2A1, and TERT mutations were identical in both components of the paired samples. Pathogenic missense or truncating mutations in TP53 and large-scale copy number alterations were more common in dedifferentiated components than in those of matched conventional components.
CONCLUSIONS.—: The results support IDH1/2, COL2A1, and TERT promoter mutations being common in dedifferentiated chondrosarcoma and as likely early events in progression, whereas inactivating mutation of TP53 and high-level copy number alterations may be later events in the dedifferentiated phenotype.
去分化软骨肉瘤是一种罕见的成人骨肿瘤,预后不良,由传统软骨肉瘤与高级别非软骨肉瘤相邻组成。去分化软骨肉瘤可能代表从分化到原始组织类型的肿瘤进展。
确定驱动从常规软骨肉瘤向高级别非软骨肉瘤进展的遗传和分子事件。
我们使用靶向下一代 DNA 测序结合免疫组织化学验证分析了 11 例去分化软骨肉瘤的常规和去分化成分的基因组景观。回顾了肿瘤的临床、放射学和病理学特征。进行了针对 479 个癌症基因和选定内含子的编码区的基于捕获的 DNA 测序。
肿瘤发生于 7 名男性(64%)和 4 名女性(36%;中位年龄 61 岁)的股骨(n = 4;36%)、肩胛骨(n = 3;27%)、骨盆(n = 3;27%)和肱骨(n = 1;9%)。所有 11 例去分化成分(100%)和 9 对配对常规软骨肉瘤成分(82%)均有足够的 DNA 进行测序。所有肿瘤(100%)均存在 IDH1 p.R132 或 IDH2 p.R172S 热点突变。7 例肿瘤(64%)显示 COL2A1 改变。TERT 启动子突变存在于 9 对中的 5 对(56%)和另外 2 对(22%)未配对的去分化成分中。配对样本中两个成分的 IDH1/2、COL2A1 和 TERT 突变完全相同。TP53 的致病性错义或截断突变和大规模拷贝数改变在去分化成分中比在匹配的常规成分中更为常见。
结果支持 IDH1/2、COL2A1 和 TERT 启动子突变在去分化软骨肉瘤中常见,并且可能是进展中的早期事件,而 TP53 失活突变和高水平拷贝数改变可能是去分化表型中的晚期事件。